Choose your location
Australia
English
Belgium
Denmark
Estonia
Finland
France
Iceland
Ireland
Latvia
Lithuania
Luxembourg
Netherlands
Norway
Portugal
Sweden
United Kingdom
The game-changing potential of GLP-1 drugs
The introduction of GLP-1s could revolutionise health care. These drugs are not only effective in treating obesity but also have the potential to combat over 200 related diseases, promising significant long-term health savings and improved patient outcomes.
Beyond diabetes and obesity
While GLP-1 receptors are concentrated in the pancreas, evidence is growing that GLP-1 drugs can interact directly with GLP-1 receptors found in other organs.
Will GLP-1s become the largest class of drugs in history?
Video Player is loading.
The ripple effects of GLP-1s
We believe we were early in understanding the promise of GLP-1s, below are just some of the ways GLP-1s have the potential to impact various sectors beyond healthcare.
Dive deeper into health care innovation
How to get exposure to health care
Our approach to investing is truly global. With one of the most extensive and experienced buy-side global research engines in the industry, our investment teams discover investment opportunities you can be confident in.
All information is as at 31 March 2024, unless specified.
Important Information
Equity Trustees Limited (“Equity Trustees”) (ABN: 46 004 031 298, AFSL: 240975) is a subsidiary of EQT Holdings Limited (ABN: 22 607 797 615), a publicly listed company on the Australian Stock Exchange (ASX:EQT). Equity Trustees and T. Rowe Price Australia Limited ("TRPAU") (ABN: 13 620 668 895, AFSL: 503741) are, respectively, the responsible entity and investment manager of the T. Rowe Price Australian Unit Trusts. Available in Australia for Wholesale Clients only.
A Target Market Determination for each T. Rowe Price Australian Unit Trust (or class of units in a Trust) is available here (www.eqt.com.au/insto). It describes who the financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where Equity Trustees Limited, the responsible entity of the T. Rowe Price Australian Unit Trusts may need to review the Target Market Determination for the financial product.
Past performance is not a reliable indicator of future performance. The price of any fund may go up or down. Investment involves risk including a possible loss to the principal amount invested. For general information purposes only, does not take into account the investment objectives, financial situation or needs of any particular investor. For further details, please refer to each fund's product disclosure statement and reference guide which are available from Equity Trustees (www.eqt.com.au/insto) or TRPAU (www.troweprice.com.au).
4061298